Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Double-Blind, Placebo-Controlled Trial of 27 mg Dolcanatide (SP‐333) to Demonstrate Colorectal Bioactivity in Healthy Volunteers

Trial Profile

Phase I Double-Blind, Placebo-Controlled Trial of 27 mg Dolcanatide (SP‐333) to Demonstrate Colorectal Bioactivity in Healthy Volunteers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2019

At a glance

  • Drugs Linaclotide (Primary)
  • Indications Constipation; Irritable bowel syndrome; Visceral pain
  • Focus Pharmacokinetics
  • Most Recent Events

    • 30 Jan 2019 Status changed from recruiting to active, no longer recruiting.
    • 24 Sep 2018 Planned End Date changed from 1 Feb 2019 to 15 Apr 2019.
    • 24 Sep 2018 Planned primary completion date changed from 1 Feb 2019 to 15 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top